诱导性多能干细胞的研究及应用

doi:10.3864/j.issn.0578-1752.2012.02.020

摘要/Abstract

摘要： 自从小鼠的胚胎成纤维细胞和鼠尾成纤维细胞重编程成为诱导多能干细胞（induced pluripotent stem cells，iPSCs）以来，iPS的研究成了干细胞研究领域的热点。与胚胎干细胞相比，iPS细胞有操作简便和高稳定性等优点可以应用于，如创建人类疾病的遗传模型，培育转基因动物用于器官移植，改善动物生产性状和抗病性，以及生物制药等领域。另外，iPSCs的产生对于解决长期以来干细胞研究领域的伦理问题和免疫排斥问题有巨大的意义，iPS结合基因治疗和细胞移植疗法的成果已经应用到了动物疾病模型上。iPS细胞技术给病人特定细胞治疗和基因针对性药品研制带来了巨大的前景。此外，该技术也提供了iPS细胞重编程机制和人类疾病的病理过程研究的新平台。然而，现阶段多能干细胞的研究只是开辟了一个新的领域，iPS技术要应用于临床还有很多工作要做。本文主要针对iPSCs的研究现状与应用前景进行讨论。

关键词: 重编程, 胚胎干细胞, 诱导性多能干细胞

Abstract: The study of induced pluripotent stem cells (iPS cells/iPSCs) has become hot spot of stem cell research since the mouse embryonic fibroblast and tail tip fibroblast were successfully reprogrammed to iPSCs. Compared with embryonic stem cells, iPS cells have many advantages, such as simple operation and high stability. The iPSCs has potential values in both the fundamental study of biology and clinical application. iPS cells’ application would be very useful in various fields, for example, creating genetic models for human diseases, obtaining transgenic animals for organ transplantation therapies, improving animal production traits and disease resistance, as well as for bio-pharmaceuticals and so on. In addition, the application of iPSCs would have a great significance for solving the long-standing problems of stem cell research ethical issues and immune rejection. With the combination of gene therapy and cell transplantation therapies, the iPSCs research findings have been applied to animal disease models and transgenic animals. And iPS cells technology elicits a great promise for patient-specific cell therapy and development of gene targeted drugs. Furthermore, the technology also provides a novel platform for the research of iPS cells reprogramming mechanism and pathological process of human disease. However, at the present stage iPSCs’ research is just beginning and there is still much work to do before iPSCs can be considered as a clinically reliable cell source. The research progress, current situation and future application prospects of iPSCs technology were discussed in the paper.

Key words: reprogramming, embryonic stem cells, induced pluripotent stem cells

苗向阳, 陈晓瑛. 诱导性多能干细胞的研究及应用[J]. 中国农业科学, 2012, 45(2): 369-375.

MIAO Xiang-Yang, CHEN Xiao-Ying. Study and Application of Induced Pluripotent Stem Cells[J]. Scientia Agricultura Sinica, 2012, 45(2): 369-375.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.chinaagrisci.com/CN/10.3864/j.issn.0578-1752.2012.02.020

https://www.chinaagrisci.com/CN/Y2012/V45/I2/369

参考文献

[1]Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4): 663-676.

[2]Vogel G. Breakthrough of the year. Reprogramming cells. Science, 2008, 322(5909): 1766-1767.

[3]Hanna J, Wernig M, Markoulaki S, Sun C W, Meissner A, Cassady J P, Beard C, Brambrink T, Wu L C, Townes T M, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science, 2007, 318(5858): 1920-1923.

[4]Zhao X Y, Li W, Lü Z, Liu L, Tong M, Hai T, Hao J, Guo C L, Ma Q W, Wang L, Zeng F Y, Zhou Q. iPS cells produce viable mice through tetraploid complementationnear-final version. Nature, 2009, 461(7260): 86-90.

[5]Zhao Y, Yin X L, Qin H, Zhu F F, Liu H S, Yang W F, Zhang Q, Xiang C G, Hou P P, Song Z H, Liu Y X, Yong J, Zhang P B, Cai J, Liu M, Li H G, Li Y Q, Qu X X, Cui K, Zhang W Q, Xiang T T, Wu Y T, Zhao Y D, Liu C, Yu C, Yuan K H, Lou J N, Ding M X, Deng H K. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell, 2008, 3(5): 475-479.

[6]Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee M J, Ji H, R. Ehrlich L I , Yabuuchi A, Takeuchi A, Cunniff K C, Hongguang H, Mckinney-Freeman S, Naveiras O, Yoon T J, Irizarry R A, Jung N, Seita J, Hanna J, Murakami P, Jaenisch R, Weissleder R, Orkin S H, Weissman I L, Feinberg A P, Daley G Q. Epigenetic memory in induced pluripotent stem cells. Nature, 2010, 467: 285-290.

[7]Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature, 2009, 458(7239): 771-775.

[8]Sun N, Panetta N J, Gupta D M, Wilson K D, Lee A, Jia F J, Hu S J, Cherry A M, Robbins R C, Longaker M T, Wu J C. Feeder-free derivation of induced pluripot- ent stem cells from adult human adipose stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(37): 15720-15725.

[9]Cai J, Li W, Su H, Qin D, Yang J, Zhu F, Xu J, He W, Guo H, Labuda K, Peterbauer A, Wolbank S, Zhong M, Li Z, Wu W, So KF, Redl H, Zeng L, Esteban M A, Pei D. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. The Journal of Biological Chemistry, 2010, 285(15): 11227-11234.

[10]Zhao X Y, Li W, Lü Z, Liu L, Tong M, Hai T, Hao J, Guo CL, Wang X, Wang L, Zeng F, Zhou Q. Efficient and rapid generation of induced pluripotent stem cells using alternative culture medium. Cell Research, 2010, 20(3): 383-386.

[11]Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell, 2009, 5(3): 237-241.

[12]Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science, 2008, 322(5903): 945-949.

[13]Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science, 2008, 322(5903): 949-953.

[14]Woltjen K, Michael I P, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P T, Gertsenstein M, Kaji K, Sung Hoon-Ki, Nagy A. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 2009, 458(7329): 766-770.

[15]Hasegawa K, Cowan A B, Nakatsuji N, Suemori H. Efficient multicistronic expression of a transgene in human embryonic stem cells. Stem Cells, 2007, 25(7): 1707-1712.

[16]Szymczak A L, Workman C J, Wang Y, Vignali K M, Dilioglou S, Vanin E F, Vignali D A. Correction of multi-gene deficiency in vivo using a single‘self-cleaving’ 2A peptide-based retroviral vector. Nature Biotechnology, 2004, 22(5): 589-594.

[17]Zhou H Y, Wu S L, Joo J Y, Zhu S Y, Han D W, Lin T X, Trauger S, Bien G, Yao S S, Zhu Y, Siuzdak G, Schöler H R, Duan L X, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 2009, 4: 381-384.

[18]Kim D, Kim C H, Moon J I, Chung Y G, Chang M Y, Han B S, Ko S, Yang E, Cha K Y, Lanza R, Kim K S. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 2009, 4: 472-476.

[19]Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Variation in the safety of induced pluripotent stem cell lines. Nature Biotechnology, 2009, 27(8): 743-745.

[20]Ho P J, Yen M L, Lin J D, Chen L S, Hu H I, Yeh C K, Peng C Y, Lin C Y, Yet S F, Yen B L. Endogenous KLF4 expression in human fetal endothelial cells allows for reprogramming to pluripotency with just OCT3/4 and SOX2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30(10): 1905-1907.

[21]Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proceedings of the National Academy of Sciences of the United States of America, 2010,107(32): 14152-14157.

[22]Stadtfeld M, Maherali N, Breault D T, Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell, 2008, 2(3): 230-240.

[23]Mikkelsen T S, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein B E, Jaenisch R, Lander E S, Meissner A. Dissecting direct reprogramming through integrative genomic analysis. Nature, 2008, 454(7200): 49-55.

[24]Warren L, Manos P D, Ahfeldt T, Loh Y H, Li H, Lau F, Ebina W, Mandal P K, Smith Z D, Meissner A, Daley G Q, Brack A S, Collins J J, Cowan C, Schlaeger T M, Rossi De J. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 2010, 7(5): 618-630.

[25]Ezashi T, Telugu B P V L, Alexenko A P, Sachdev S, Sinha S, Roberts R M. Derivation of induced pluripotent stem cells from pig somatic cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(27): 10993-10998.

[26]Wu Z, Chen J J, Ren J T, Bao L, Liao J, Cui C, Rao L J, Li H, Gu Y J, Dai H M, Zhu H, Teng X K, Cheng L, Xiao L. Generation of pig-induced pluripotent stem cells with a drug-inducible system. Journal of Molecular Cell Biology, 2009, 1(1): 46-54.

[27]Li Y, Cang M, Lee A S, Zhang K, Liu D. Reprogramming of sheep fibroblasts into pluripotency under a drug-inducible expression of mouse-derived defined. PLoS One 6:e15947 (2011).

[28]Bao L, He L X Z, Chen J J, Wu Z, Liao J, Rao L J, Ren J T, Li H, Zhu H, Qian L, Gu Y J, Dai H M, Xu X, Zhou J Q, Wang W, Cui C, Xiao L. Reprogramming of ovine adult fibroblasts to pluripotency via drug-inducible expression of defined factors. Cell Research, 2011, 21: 600-608.

[29]Hanna J, Wernig M, Markoulaki S, Sun C W, Meissner A, Cassady J P, Beard C, Brambrink T, Wu L C, Townes T M, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science, 2007, 318(5858): 1920-1923.

[30]Ebert D, Yu J Y, Jr Rose F F, Mattis V B, Lorson C L, Thomson J A, Svendsen C N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 2009, 457(7227): 277-280.

[31]Lee G, Papapetrou E P, Kim H, Chambers S M, Tomishima M J, Fasano C A, Ganat Y M, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature, 2009, 461(7262): 402-406.

[32]Dimos J T, Rodolfa K T, Niakan K K, Weisentha l L M, Mitsumoto H, Chung W, Croft G F, Saphier G, Leibel R, Goland R, Wichterle H, Henderson C E, Eggan K. Induced pluripotent stem cells generat-ed from patients with ALS can be differentiated into motor neurons. Science, 2008, 321(5893): 1218-1221.

[33]Park I H, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch M W, Cowan C, Hochedlinger K, Daley G Q. Disease-specific induced pluripotent stem cells. Cell, 2008, 134(5): 877-886.

[34]Soldner F, Hockemeyer D, Beard C, Gao Q, Bell G W, Cook E G, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 2009, 136(5): 964-977.

[35]Rashid S T, Corbineau S, Hannan N, Marciniak S J, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas D A, Vallier L. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. The Jouranl of Clinical Investigation, 2010, 120(90): 3127-3136.

[36]Noritaka Y, Shiro B, Shinji K, Akira N, Takahiro M, Hiraku D, Shinya Y, Tatsutoshi N, Toshio H. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochemical and Biophysical Research Communications, 2009, 387(3): 482-488.